Almirall S.A
Research Almirall S.A (E2Z) on Bullrun: valuation model: 25.2% overvalued, market cap EUR 2.44B, P/E 59.1, dividend yield 1.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerE2Z
- ExchangeF
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal25.2% overvalued
- Market capEUR 2.44B
- P/E59.1
- Dividend yield1.7%
- Financial periodFY2024
- RevenueEUR 985.72M
- Revenue growth10.2%
- Net incomeEUR 10.15M
- Free cash flowEUR 130.93M
Valuation Snapshot
Bullrun's latest valuation model marks Almirall S.A as 25.2% overvalued; latest market cap is EUR 2.44B; P/E is 59.1; dividend yield is 1.7%.
About Almirall S.A
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.
Frequently asked questions
Is Almirall S.A overvalued or undervalued?
Bullrun's valuation model currently marks Almirall S.A as 25.2% overvalued.
What is Almirall S.A's market cap?
Almirall S.A's market capitalization is EUR 2.44B.
What is Almirall S.A's P/E ratio?
Almirall S.A's price-to-earnings (P/E) ratio is 59.1.
Does Almirall S.A pay a dividend?
Almirall S.A has a dividend yield of 1.7%.
What does Almirall S.A do?
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa.